ATE541588T1 - Konjugat von perphenazin und gaba und seine verwendungen - Google Patents

Konjugat von perphenazin und gaba und seine verwendungen

Info

Publication number
ATE541588T1
ATE541588T1 AT02772790T AT02772790T ATE541588T1 AT E541588 T1 ATE541588 T1 AT E541588T1 AT 02772790 T AT02772790 T AT 02772790T AT 02772790 T AT02772790 T AT 02772790T AT E541588 T1 ATE541588 T1 AT E541588T1
Authority
AT
Austria
Prior art keywords
residue
chemical moiety
psychotic drug
perphenazine
gaba
Prior art date
Application number
AT02772790T
Other languages
English (en)
Inventor
Abraham Nudelman
Ada Rephaeli
Irit Gil-Ad
Abraham Weizman
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE541588T1 publication Critical patent/ATE541588T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
AT02772790T 2001-09-27 2002-09-29 Konjugat von perphenazin und gaba und seine verwendungen ATE541588T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32493601P 2001-09-27 2001-09-27
PCT/IL2002/000795 WO2003026563A2 (en) 2001-09-27 2002-09-29 Conjugated anti-psychotic drugs and uses thereof

Publications (1)

Publication Number Publication Date
ATE541588T1 true ATE541588T1 (de) 2012-02-15

Family

ID=23265759

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772790T ATE541588T1 (de) 2001-09-27 2002-09-29 Konjugat von perphenazin und gaba und seine verwendungen

Country Status (10)

Country Link
EP (2) EP1429844B1 (de)
JP (3) JP4521187B2 (de)
KR (4) KR100996239B1 (de)
CN (2) CN101445494A (de)
AT (1) ATE541588T1 (de)
CA (1) CA2461663A1 (de)
ES (2) ES2399977T3 (de)
IL (2) IL161083A0 (de)
MX (1) MXPA04002912A (de)
WO (1) WO2003026563A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
ES2399977T3 (es) * 2001-09-27 2013-04-04 Ramot At Tel Aviv University Ltd. Conjugado de perfenazina o flufenazina con ácidos carboxílicos
EP2272537A3 (de) 2005-06-07 2014-10-22 Ramot at Tel-Aviv University Ltd. Salzen von Konjugaten bestehend aus psychotropischen Arzneimitteln und Prozessen zu ihrer Herstellung
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
CN101506188B (zh) * 2006-06-22 2014-01-15 雷蒙特亚特特拉维夫大学有限公司 作为具外周系统限制活性药物的五羟色胺再摄取抑制剂
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
WO2008010223A2 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
TW200829238A (en) * 2006-11-30 2008-07-16 Cenerx Biopharma Inc Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
AU2010329440A1 (en) 2009-12-09 2012-08-09 Bar-Ilan University Methods of improving cognitive functions
AU2014202425B2 (en) * 2009-12-31 2015-11-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
WO2011104637A2 (en) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
RS58335B1 (sr) 2010-03-11 2019-03-29 Kempharm Inc Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
CN111329865A (zh) * 2020-03-30 2020-06-26 华东理工大学 奋乃静在制备治疗子宫内膜癌的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227708A (en) * 1957-09-11 1966-01-04 Olin Mathieson Trifluoromethyl phenothiazines
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
GB1460713A (en) * 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3978216A (en) * 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3956493A (en) * 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
GB1540842A (en) * 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
CN1375287A (zh) * 2001-03-16 2002-10-23 王玉万 含氯氰碘柳胺或其钠盐的兽用混悬注射剂
ES2399977T3 (es) * 2001-09-27 2013-04-04 Ramot At Tel Aviv University Ltd. Conjugado de perfenazina o flufenazina con ácidos carboxílicos

Also Published As

Publication number Publication date
KR100996239B1 (ko) 2010-11-23
JP2010090170A (ja) 2010-04-22
WO2003026563A3 (en) 2004-03-18
JP2005503423A (ja) 2005-02-03
WO2003026563A9 (en) 2004-04-22
IL161083A0 (en) 2004-08-31
EP2275143B1 (de) 2012-12-19
MXPA04002912A (es) 2004-07-05
CN100558365C (zh) 2009-11-11
EP2275143A2 (de) 2011-01-19
IL202291A0 (en) 2011-07-31
KR20090130150A (ko) 2009-12-17
WO2003026563A2 (en) 2003-04-03
ES2379544T3 (es) 2012-04-27
CA2461663A1 (en) 2003-04-03
KR20040062554A (ko) 2004-07-07
JP4521187B2 (ja) 2010-08-11
KR101238452B1 (ko) 2013-02-28
KR20100097224A (ko) 2010-09-02
EP1429844B1 (de) 2012-01-18
EP1429844A2 (de) 2004-06-23
CN101445494A (zh) 2009-06-03
CN1596141A (zh) 2005-03-16
KR20120032547A (ko) 2012-04-05
EP1429844A4 (de) 2006-06-07
JP2014015472A (ja) 2014-01-30
ES2399977T3 (es) 2013-04-04
EP2275143A3 (de) 2011-01-26

Similar Documents

Publication Publication Date Title
IL202291A0 (en) Conjugated psychotropic drugs and uses thereof
BR9904998A (pt) Derivados de hidroxamida do ácido 5-oxo-pirrolidina-2-carboxìlico
DK0623607T3 (da) Benzofuranyl- og -thiophenyl-alkancarboxylsyrederivater
DE69739415D1 (de) Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten
DE69023171D1 (de) Kondensierte heterozyklische Verbindungen, ihre Herstellung und Verwendung.
TW200420569A (en) New ruthenium complexes as (pre)catalysts for the metathesis reaction, 2-alkoxy-5-nitrostyrene derivatives as intermediates and the method of their manufacturing
ATE273992T1 (de) Konjugate von ascorbinsäure und phytosterolen oder phytostanolen und ihre verwendung zur behandlung von gefässkrankheiten
DE69835877D1 (de) Trizyklische verbindungen
MX2007004763A (es) Acidos carboxilicos (bifenilo) y derivados de los mismos.
ATE442129T1 (de) Camptothecin-carboxylat-formulierungen
BR0317731A (pt) Compostos de ácido cicloalqueno dicarboxìlicos como agentes antiinflamatórios, imunomoduladores e antiproliferativos
ATE368645T1 (de) Aminosäurederivate als hiv-protease-inhibitoren
DK1134261T3 (da) Kønrøg
ES2105953B1 (es) Perfeccionamientos en el objeto de la patente de invencion 9102594 por procedimiento de obtencion de compuestos derivados de piridina.
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
BR9105629A (pt) Composicao agroquimica,e,processo para preparar ou formular uma composicao agroquimica
DE68919378D1 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung.
BR0208131A (pt) Derivados biguanida
ATE517626T1 (de) Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen
DE60022416D1 (de) Verfahren zur Herstellung von 2-Alkyl-3-aminothiophen Derivate und 3-Aminothiophen Derivate
ATE419238T1 (de) Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz
DK0554794T3 (da) Aminobenzoesyrederivater
DE60003795D1 (de) Sulfofukosylacylglycerin-derivate und ihre anwendung als medikamente
ATE228134T1 (de) Kondensierte pyrimidinderivate und diese enthaltende pharmazeutische zubereitungen
ATE279182T1 (de) Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c